Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial

Investigate the effects of photobiomodulation (PBM) on the expression of IL-10 and nitrites in individuals with Relapsing-Remitting multiple sclerosis (MS), as these biomarkers play a fundamental role in the physiopathology of the disease. The modulation of IL-10 and nitrites through treatment with...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-04, Vol.15 (4), p.e0230551-e0230551
Main Authors: Silva, Tamiris, Fragoso, Yara Dadalti, Destro Rodrigues, Maria Fernanda Setúbal, Gomes, Andréa Oliver, da Silva, Fernanda Cordeiro, Andreo, Lucas, Viana, Ariane, Teixeira da Silva, Daniela de Fátima, Chavantes, Maria Cristina, Tempestini Horliana, Anna Carolina Ratto, De Angelis, Kátia, Deana, Alessandro Melo, Branco, Luciana Prats, Santos Fernandes, Kristianne Porta, Motta, Lara Jansiski, Mesquita-Ferrari, Raquel Agnelli, Bussadori, Sandra Kalil
Format: Article
Language:English
Subjects:
Biological markers
Biology and Life Sciences
Biomarkers
Clinical trials
Consent
Cytokines
Disabilities
Diseases
Health sciences
Health services
Interleukin 10
Interleukins
Irradiation
Light therapy
Medicine and Health Sciences
Multiple sclerosis
Nitrites
Peripheral blood
Physical Sciences
Power (Philosophy)
Product development
Proteins
Recurrence (Disease)
Rehabilitation
Serum levels
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Investigate the effects of photobiomodulation (PBM) on the expression of IL-10 and nitrites in individuals with Relapsing-Remitting multiple sclerosis (MS), as these biomarkers play a fundamental role in the physiopathology of the disease. The modulation of IL-10 and nitrites through treatment with PBM may be a novel treatment modality for MS. A randomized, uncontrolled, clinical trial was conducted involving 14 individuals with a diagnosis of Relapsing-Remitting MS and a score of up to 6.0 on the Expanded Disability Status Scale (EDSS). Group 1 -PBM in the sublingual region; Group 2 -PBM over the radial artery. Irradiation was administered with a wavelength of 808 nm and output power of 100 mW for 360 seconds twice a week, totaling 24 sessions. Peripheral blood was analyzed for the determination of serum levels of IL-10 and nitrites. After treatment with PBM, the expression of IL-10 increased in both the sublingual group (pre-treatment: 2.8 ± 1.4 pg/ml; post-treatment: 8.3 ± 2.4 pg/ml) and the radial artery group (pre-treatment: 2.7 pg/ml ± 1.4; post-treatment: 11.7 ± 3.8 pg/ml). In contrast, nitrite levels were not modulated in the sublingual group (pre-treatment: 65 ± 50 nmol/mg protein; post-treatment: 51 ± 42 nmol/mg protein) or the radial artery group (pre-treatment: 51 ± 16 nmol/mg protein; post-treatment: 42 ± 7 nmol/mg protein). Treatment with PBM positively modulated the expression of IL-10 but had no effect on nitrite levels. Further studies should be conducted with a larger sample and a control group, as PBM may be a promising complementary treatment for the management of MS. This trial is registered at ClinicalTrials.gov. Identifier: NCT03360487.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0230551